Enliven Therapeutics, Inc. (ELVN)

Enliven Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	149.22	100.2	75.59	48.31	47.7	4.94
Short-Term Investments	171.34	153.01	0	41.97	40.52	23.97
Cash & Cash Equivalents	320.56	253.2	75.59	90.28	88.22	28.91
Cash Growth	9.72%	234.97%	-16.27%	2.33%	205.19%	291.59%
Other Current Assets	16.64	12.95	2.16	2.42	2.18	1.72
Total Current Assets	337.2	266.15	77.75	92.7	90.41	30.62
Property, Plant & Equipment	0.92	1.06	1.52	0.78	0.35	0.44
Other Long-Term Assets	4.65	4.65	4.03	0.18	0.09	2.23
Total Long-Term Assets	5.58	5.72	5.55	0.95	0.44	2.67
Total Assets	342.78	271.87	83.3	93.65	90.84	33.3
Accounts Payable	2.73	0.53	3.44	2.36	1.97	1.66
Current Debt	0	0	0	0.25	0	0
Other Current Liabilities	22.3	25.36	6.28	4.6	4.28	2.54
Total Current Liabilities	25.03	25.89	9.72	7.21	6.25	4.2
Long-Term Debt	0	0	0	0.41	0	0
Other Long-Term Liabilities	0.03	0.07	0.66	0	0.16	0.18
Total Long-Term Liabilities	0.03	0.07	0.66	0.41	0.16	0.18
Total Liabilities	25.07	25.96	10.37	7.62	6.41	4.38
Total Debt	0	0	0	0.65	0	0
Retained Earnings	-177.19	-154.45	-82.86	-147.5	-96.11	-54.75
Comprehensive Income	-0.05	0.14	0	-0.02	0	0.03
Shareholders' Equity	317.71	245.91	-76.83	86.03	84.44	-48.85
Net Cash / Debt	320.56	253.2	75.59	89.63	88.22	28.91
Net Cash / Debt Growth	9.72%	234.97%	-15.66%	1.59%	205.19%	291.59%
Net Cash Per Share	7.62	7.12	24.19	16.55	25.34	164.61
Working Capital	312.17	240.26	68.04	85.49	84.16	26.43
Book Value Per Share	7.56	6.92	-24.59	15.89	24.25	-278.16

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).